DISCOVERIES (ISSN 2359-7232), 2018, January-March issue

CITATION: 

Submitted: March 29, 2018; Revised: March 31, 2018; Accepted: April 3, 2018; Published: April 4, 2018;

 GO BACK to 2018, January-March issue

 GO BACK to DISCOVERIES

New FDA approved antibacterial drugs: 2015-2017

Stefan Andrei (1,#,*), Liana Valeanu (2,3,#), Radu Chirvasuta (4), Mihai-Gabriel Stefan (2,3)

(1) Intensive Care Unit, Centre Hospitalier Lyon Sud, Pierre Benite, France 

(2) Department of Cardiac Anesthesia and Intensive care, Emergency Institute for Cardiovascular Diseases “Prof. C.C. Iliescu” Bucharest, Romania 

(3) Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  

(4) Anaesthetics Department, Lister Hospital, Stevenage, UK

# These authors contributed equally to this manuscript

*Corresponding author: Stefan Andrei, MD, Intensive Care Unit, Centre Hospitalier Lyon Sud, Pierre Benite, France, stefan.m.andrei@gmail.com

Abstract

Increasing bacterial resistance to antibiotics is a worldwide ongoing issue. Urgent need for new antibacterial agents has resulted in significant research efforts, with new molecules proposed for use in clinical practice. However, many groups highlight that this process does not have an optimal rhythm and efficacy, to fully combat highly adaptive germs, particularly in the intensive care units. 

This review focuses on the last three years of novel FDA approved antibacterial agents (2015-2017): ceftazidime/avibactam, obiltoxaximab, bezlotoxumab, delafloxacin, meropenem/vaborbactam, ozenoxacin. Ceftazidime/avibactam and meropenem/ vaborbactam are new players in the field of resistant bacteria treatment. Ceftazidime/avibactam is validated in selected patients with complicated urinary or intra-abdominal infections, hospital and ventilator-associated pneumonia. Meropenem/ vaborbactam gained approval for the cases of complicated urinary tract infections. Other potential indications are under investigation, widened and validated by future studies. Obiltoxaximab is a monoclonal antibody that can be used in the prevention and treatment of inhalational anthrax. Bezlotoxumab monoclonal antibody is an useful and specific tool for the management of recurrent Clostridium difficile infection. Delafloxacin is approved for patients with acute skin or skin structure infections.

Access full text of the manuscript here: Full text (pdf)

References

1. Levy, S. B. & Bonnie, M. Antibacterial resistance worldwide: Causes, challenges and responses. Nat. Med. 2004, 10: S122–S129.

2. Bretonnière, C. et al. Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med. 2015. 41: 1181–1196.

3. Hornsey, M. & Wareham, D. W. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 2011, 55: 3534–3537.

4. Bush, K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int. J. Antimicrob. Agents 2015, 46: 483–493.

5. Martinez, J. L. General principles of antibiotic resistance in bacteria. Drug Discov. Today Technol. 2014, 11: 33–39.

6. Bassetti, M. et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015, 41: 776–795.

7. Delory, T. et al. Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: An interrupted time-series analysis. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32: 1599–1604.

8. Álvarez-Lerma, F. et al. Prevention of Ventilator-Associated Pneumonia. Crit. Care Med. 1 (2017).

9. Derde, L. P. G et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Inf. Dis. 2014, 14: 31–39.

10. Jacobs, M. et al. Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis. Antimicrob. Agents Chemother. 2016, 60: 1788–1793.

11. Ruppé, É., Woerther, P.-L. & Barbier, F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann. Intensive Care 2015, 5: 21.

12. Zhanel, G. G. et al. Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination. Drugs 2013, 73: 159–177.

13. Lagacé-Wiens, P., Walkty, A. & Karlowsky, J. Ceftazidime and avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014, 13. doi:10.2147/CE.S40698

14. Levasseur, P. et al. In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates. Antimicrob. Agents Chemother. 2012, 56: 1606–1608.

15. Avycaz FDA Highlights of prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206494s003lbl.pdf  Accessed on 29 March 2018.

16. Zavicefta EMA summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/

004027/WC500210234.pdf  Accessed on 29 March 2018.

17. Mazuski, J. E. et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infection – Results from a Randomized, Controlled, Double-Blind, Phase 3 Program. 2016, 33.

18. Carmeli, Y. et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect. Dis. 2016, 16: 661–673.

19. Vazquez, J. A. et al. Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 2012, 28: 1921–1931.

20. Torres, A. et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect. Dis. 2018, 18: 285–295.

21. Shields, R. K. et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1. Clin. Infect. Dis. 2016, 63: 1615–1618.

22. Spellberg, B. & Bonomo, R. A. Editorial Commentary : Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: ‘We’re Gonna Need a Bigger Boat’. Clin. Infect. Dis. 2016, 63: 1619–1621.

23. ANTHIM (obiltoxaximab). FDA Highlights of prescribing information. Available at  https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125509lbl.pdf Accessed 29 March 2018.

24. Hou, A. W. & Morrill, A. M. Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection. Ann. Pharmacother. 2017, 51: 908–913.

25. Tsai, C.-W. & Morris, S. Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration ‘Animal Rule’. Front. Microbiol. 2015, 6: 1320.

26. Yamamoto, B. J. et al. Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity. Antimicrob. Agents Chemother. 2016, 60: 5787–5795.

27. Yamamoto, B. J. et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob. Agents Chemother. 2016, 60: 5796–5805.

28. Nagy, C. et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule: Obiltoxaximab Dose for Anthrax Treatment. Clin. Transl. Sci. 2017, 10: 12–19.

29. Nagy, C. F., Leach, T. S., King, A. & Guttendorf, R. Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans. Clin. Pharmacol. Drug Dev. 2017. doi:10.1002/cpdd.410.

30. Center for Drug Evaluation and Research. Application Number: 761046Orig1s000. Summary Review. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2016/761046Orig1s000Approv.pdf Accessed on 28 March 2018.

31.          Center for Drug Evaluation and Research. Application Number: 761046Orig1s000. Microbiology/ Virology Review. Available at https://www.accessdata. fda.gov/ drugsatfda_docs/nda/2016/761046Orig1s000 MicroR.pdf Accessed on 28 March 2018.

32. Orth, P. et al. Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography. J. Biol. Chem. 2014, 289: 18008–18021.

33. Deeks, E. D. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence. Drugs 2017, 77: 1657–1663.

34. Center for Drug Evaluation and Research. Application Number: 761046Orig1s000. Pharmacology Review. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046Orig1s000PharmR.pdf Accessed on 28 March 2018.

35. Prabhu, V. S. et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clin. Infect. Dis. 2018, 66: 355–362.

36. Wilcox, M. H. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N. Engl. J. Med. 2017, 376: 305–317.

37. Preventing recurrence of Clostridium difficile infection: bezlotoxumab. Evidence update from NICE. Published June 2017. Available at https://www.nice.org.uk/advice/es13/chapter/Evidence-review Accessed on 27 March 2018.

38. Hernandez, L. D. et al. Epitopes and Mechanism of Action of the Clostridium Difficile Toxin A-Neutralizing Antibody Actoxumab. J. Mol. Biol. 2017, 429: 1030–1044.

39. Bassetti, M., Pecori, D., Cojutti, P., Righi, E. & Pea, F. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin. Drug Metab. Toxicol. 2017, 13: 1193–1200.

40. Cho J.C. et al., What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone, Pharmacotherapy. 2018, 38(1): 108-121.

41. Pullman J. et al., Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study, J Antimicrob Chemother. 2017, 72(12): 3471-3480.

42. O’Riordan W. et al, A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study, Clin Infect Dis. 2018 Mar 6.

43. Baxdela (delafloxacin). FDA Highlights of prescribing information. Available at https:// www.accessdata.fda.gov/drugsatfda_docs/ label/2017/208610s000.208611s000lbl.pdf Accessed on 25 March 2018.

44. A phase 3, multicenter, randomized, double‐blind, comparator‐controlled study to evaluate the safety and efficacy of intravenous to oral delafloxacin in adult subjects with community‐acquired bacterial pneumonia.  Available at   https://clinicaltrials.gov/ct2/show/NCT026 79573   Accessed on 25 March 2018.

45. Hoover R. et al., Pharmacokinetics of Intravenous Delafloxacin in Patients with End-Stage Renal Disease, J Clin Pharmacol. 2018 Mar 14.

46. Hoover R. et al., Clinical Pharmacology of Delafloxacin in Patients with Hepatic Impairment, J Clin Pharmacol. 2017, 57(3): 328-335.

47. Vabomere FDA Highlights of prescribing information. Available at https://www.accessdata.fda.gov /drugsatfda_docs/label/2017/209776lbl.pdf Accessed on 27 March 2018.

48. Zhanel G.G. et al., Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations, Drugs. 2018, 78(1): 65-98.

49. Cho J.C. et al., Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination, Ann Pharmacother. 2018 Mar 1.

50. Kaye K.S. et al., Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial, JAMA. 2018, 319(8): 788-799.

51. Bassetti M. et al., New antibiotics for ventilator-associated pneumonia, Curr Opin Infect Dis. 2018, 31(2): 177-186.

52. Paterson D.L. et al. Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients, Open Forum Infectious Diseases 2017, 4 (suppl_1): S537.

53. Rubino C.M. et al., Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment, Antimicrob Agents Chemother. 2018, 62(3)

54. Ozenoxacin. FDA Highlights of prescribing information. Available at https://www.accessdata.fda.gov /drugsatfda_docs/label/2017/208945lbl.pdf Accessed on 24 March 2018.

55. Gropper S. et al., Systemic bioavailability and safety of twice-daily topical ozenoxacin 1%  cream in adults and children with impetigo, Future Microbiol. 2014, 9(8 Suppl): S33-40.

56. Gropper S. et al., Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial, Future Microbiol. 2014, 9(9):1013-23.

57. WHO, Antibacterial agents in clinical development, May 2017. Available at http://www.who.int/medicines/news/2017/ IAU_AntibacterialAgentsClinicalDevelopment_webfinal_2017_09_19.pdf Accessed on 29 March 2018.

58. Choi J.J.and McCarthy M.W. Cefiderocol: A novel siderophore cephalosporin, Expert Opinion on Investigational Drugs, 2018.

59. Wyckoff E.E. et al. Catechol Siderophore Transport by Vibrio cholerae. J Bacteriol. 2015, 197(17): 2840‐9.

60. Hackel M.A. et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram‐Negative Bacilli from North America and Europe, Including Carbapenem‐Nonsusceptible Isolates (SIDERO‐WT‐2014 Study). Antimicrob Agents Chemother. 2017, 61(9): 2017.

61. Nichols D . et al. Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl Environ Microbiol. 2010, 76: 2445–50.

62. Lewis, K. Platforms for antibiotic discovery. Nature Rev. Drug Discov. 2013, 12: 371–387.

63. Ling L.L., et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015, 517: 455–9.

64. Homma T., et al. Dual targeting of cell wall precursors by teixobactin leads to cell lysis. Antimicrob Agents Chemother.  2016, 60(11): 6510–6517.

65. Arias C. A and Murray B. E. A New Antibiotic and the Evolution of Resistance. N Engl J Med.  2015, 372(12): 1168–1170.

66. Hover B.M. et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens.  Nature Microbiology. 2018, 3(4): 415-422.